Myovant Sciences Ltd (MYOV) Stock
MYOV is no longer traded. Myovant Sciences was acquired by Sumitovant on March 10, 2023.
Each MYOV share was exchanged for $27.00 in cash. Prices on this page are historical; the last trade was March 9, 2023 at $26.98.
Myovant Sciences stock price history
MYOV final trading statistics
- Final close
- $26.98
- Final trading day
- Mar 9, 2023
- Market cap at delisting
- $2.62B
- Shares outstanding
- 97.26M
- Final 52-week range
- $7.67 – $27.06
- Avg. volume (final 3 mo.)
- 1,039,461
- All-time high (split-adj.)
- $27.62 · Dec 2020
- All-time low (split-adj.)
- $4.20 · Oct 2019
- Return since IPO
- +103.5%
- Beta
- 2.15
- Book value / share
- -$5.75
- Price / book
- -4.69
Myovant Sciences annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $230.97M | -$206.0M | -$2.21 |
| FY2021 | $59.32M | -$255.1M | -$2.83 |
| FY2020 | $0.00 | -$289.0M | -$3.37 |
| FY2019 | $881.0K | -$273.6M | -$4.08 |
| FY2018 | $0.00 | -$143.3M | -$2.40 |
Last five fiscal years reported before the delisting; fiscal year ending March. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Myovant Sciences Ltd
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
Myovant Sciences stock FAQ
What happened to Myovant Sciences stock?
Myovant Sciences was acquired by Sumitovant on March 10, 2023. Shareholders received $27.00 in cash for each share. MYOV stock stopped trading on the NYSE, with a final close of $26.98 on March 9, 2023.
What did Myovant Sciences shareholders receive?
Each MYOV share was converted into $27.00 in cash. The deal was valued at about $1.7 billion.
Is MYOV stock still trading?
No. MYOV was delisted from the NYSE on March 10, 2023 and no longer trades on a U.S. exchange.
What was the last price of MYOV stock?
MYOV closed at $26.98 on its final trading day, March 9, 2023, for a market value of about $2.62B.
What were Myovant Sciences's revenue and earnings in its last full fiscal year?
Myovant Sciences reported revenue of $230.97M and net income of -$206.0M in fiscal 2022, its last full year as a public company.
When did Myovant Sciences go public?
Myovant Sciences Ltd stock began trading on October 27, 2016.